If you’ve already registered, please click here to log in to the webcast.

Autoantibodies are emerging as promising biomarkers for many cancers including cutaneous melanoma (CM), offering potential advantages in early detection, prognosis, and treatment monitoring. These antibodies target tumour-associated antigens (TAAs) and can be detected in the sera of melanoma patients, often before clinical symptoms appear.

This webcast will highlight novel technologies that enable the detection of autoantibodies by screening human serum samples against more than 80% of the human proteome. The presence of autoantibodies may indicate immune recognition of melanoma cells and correlate with disease progression, response to therapy and occurrence of treatment-related side effects. While autoantibody panels could enhance diagnostic accuracy and disease monitoring, challenges remain in standardising these biomarkers due to variability in their data analysis pipeline, immune response variability and specificity concerns. Future research integrating autoantibody profiles with other molecular and imaging biomarkers may improve melanoma detection and patient outcomes.

You will learn:

• What is the evidence that autoantibodies may be suitable cancer biomarkers?
• What specific autoantibodies have been identified in melanoma patients, and how they enable early melanoma detection or correlate with disease progression, prognosis and prediction of treatment response
• Challenges and future directions for integrating autoantibody biomarkers into clinical practice for melanoma management 

This webcast has been produced by CDI Labs who retain sole responsibility for content. About this content